This Article Full Text Full Text (PDF) All Versions of this Article: 92/8/3013    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bechtold, S. Articles by Schwarz, H. P. Search for Related Content PubMed PubMed Citation Articles by Bechtold, S. Articles by Schwarz, H. P. Related Collections Pediatric Endocrinology

Growth Hormone Increases Final Height in Patients with Juvenile Idiopathic Arthritis: Data from a Randomized Controlled Study

University Children’s Hospital (S.B., R.D.P., W.B., H.P.S.), Division of Endocrinology and Diabetology, D-80337 Munich, Germany; and Children’s Hospital for Rheumatology (P.R., R.H., H.M.), D-82467 Garmisch-Partenkirchen, Germany

Address all correspondence and requests for reprints to: S. Bechtold, M.D., Kinderklinik und Kinderpoliklinik, Im Dr. von Haunerschen Kinderspital, Pediatric Endocrinology, Lindwurmstrasse 4, D-80337 München, Germany. E-mail: Susanne.Bechtold{at}med.uni-muenchen.de.

Background: GH treatment stimulates growth in short children with juvenile idiopathic arthritis (JIA). The extent to which this therapy increases final height is not known.

Methods: Thirty-one growth-retarded children with systemic and polyarticular idiopathic arthritis were enrolled in this controlled study. After a mean observational time of 8.4 yr, final height was reached in 13 patients (seven females and six males) treated with GH for a mean of 6.7 yr in a dose of 0.33 mg/kg body weight per week. Eighteen patients (12 females and six males) served as an untreated control group.

Results: Mean increment in height in the treatment group was 1.6 ± 0.8 SD, whereas the patients of the control group lost 0.7 ± 1.8 SD. Overall, mean final height in the treatment group was –1.6 SD and in the control group –3.4 SD. More GH-treated patients reached a final height within target height than untreated patients (11 of 13 vs. four of 18). Disease activity markers had a significant influence on height outcome. After adjustment for baseline and average disease activity, the difference between treatment and control group was still significant (mean 1.5 SD). Patients with a moderate overall disease activity profited most from GH treatment. No adverse events were noted throughout the study.

Conclusion: Our data suggest that long-term GH therapy has a beneficial effect on growth and final height in the majority of growth retarded children with severe forms of JIA.